Spotlight Interview with JOGI AMIT, GENERAL MANAGER at Syngene

 

 

 

 

 

  1. Why did you decide to do a webinar with us?

I have been working in the Biologics Manufacturing operations space for over two decades now, and it has been a very rewarding and productive experience. A webinar session hosted on BR webinar seemed to be the right platform for sharing my knowledge and ideas with the scientific community.

  1. What will the audience gain from attending your webinar?

An efficient and successful technology transfer to manufacturing plant is the outcome of a systemic approach to scale up. The systemic approach depends critically on understanding of engineering parameters as well as the team’s scientific and practical knowledge. At Syngene, we have successfully devised a systemic approach demonstrating ‘First-Time Right’ technology transfer processes to our GMP manufacturing plant. We have achieved fifteen successful technology transfers in the last two and half years, without any failure or major technical glitches.

This webinar will give the audience a good understanding on (i) key questions to enable decision for way-forward; (ii) risk analysis and mitigation strategies; (iii) parameter selection and evaluation for technology transfer. I am optimistic that the Biologics community, both in academics and industry, will benefit immensely from the knowledge shared in this webinar.

  1. How did you get into the industry and what do you most enjoy about your role?

 After earning a Ph.D. in Microbiology and working as research fellow in the Department of Biotechnology during this tenure, I joined a contract research organization in Hyderabad.  There, our dynamic, multi-disciplinary team of researchers created unique working model of a platform process for the different variety of expression systems.

Over a decade ago, I moved to a global CRO, Syngene. Syngene has provided me greater opportunities to partner with global pharma leaders to apply findings from various fields of biopharmaceutical research, development and manufacturing towards new drug development programs of clients. Along with my team of bioengineers and development scientist, I help biopharma organizations make informed decisions on their early-phase drug substance development pipeline and optimization of scale up/technology transfer approaches. I have taken different roles at Syngene from discovery research to process development to manufacturing science and technology to manufacturing operation. It gives me great satisfaction when a client provides feedback on how our approaches helped them arrive at the best decision and expedite timelines of their milestones. It also gives me immense pleasure to innovative way of addressing client’s requirements and expediate timeline targeting “First Time Right”. Identifying and nurturing the unique skillsets of each of my team members is an aspect of my role that I particularly enjoy. The challenge of continuously delivering enhanced value to our clients while working within the demanding timelines of the industry is what drives me every single day!

  1. What are you hoping to achieve in the future in your personal and professional life?

I wish to share my practical knowledge that I have gained over the years on Upstream Development, Manufacturing Science and Technology (MSAT), and Manufacturing Operations, with the scientific community to encourage an environment of collaboration and group learning. Working on customized solutions to scientific problems is something that keeps me motivated, and I hope to continue working in this exciting field for many more years.

  1. What would someone be surprised to know about you?

 All through my academic life, from undergraduate studies to Ph.D, I enjoyed scientific research to decipher the unknown and publish the work in reputed international journals and present it in front of the scientific community.

I have authored in multiple publications, am an active speaker in international conferences and have also co-authored a book.

Register Now: https://bit.ly/2MpT4OZ

Leave a Reply

Your email address will not be published. Required fields are marked *